This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Galen Limited

Seagoe Industrial Estate, Craigavon, Co Armagh, Northern Ireland, BT63 5UA, Ireland
Telephone: +44 (0)28 3833 4974
Fax: +44 (0)28 3835 0206
Medical Information e-mail:

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 07/02/2013
SPC Laxido Orange, powder for oral solution

Go to top of the page
1. Name of the medicinal product

Laxido Orange, powder for oral solution.

Go to top of the page
2. Qualitative and quantitative composition

Each sachet contains the following quantitative composition of active ingredients:

Macrogol 3350


Sodium Chloride


Sodium Hydrogen Carbonate


Potassium Chloride


The content of electrolyte ions per sachet following reconstitution in 125ml of water is equivalent to:





Hydrogen Carbonate (Bicarbonate)




For a full list of excipients, see section 6.1.

Go to top of the page
3. Pharmaceutical form

Powder for oral solution. Single-dose sachet containing a free flowing white powder.

Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

For the treatment of chronic constipation. Laxido Orange is also effective in resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon.

Go to top of the page
4.2 Posology and method of administration

Laxido Orange is for oral use.

Chronic Constipation:

A course of treatment for chronic constipation with Laxido Orange does not normally exceed 2 weeks, although this can be repeated if required. As for all laxatives, prolonged use is not usually recommended. Extended use may be necessary in the care of patients with severe chronic or resistant constipation, secondary to multiple sclerosis or Parkinson's Disease, or induced by regular constipating medication in particular opioids and antimuscarinics.

Adults, adolescents and the elderly: 1-3 sachets daily in divided doses, according to individual response. For extended use, the dose can be adjusted down to 1 or 2 sachets daily.

Children below 12 years old: Not recommended.

Faecal Impaction:

A course of treatment for faecal impaction with Laxido Orange does not normally exceed 3 days.

Adults, adolescents and the elderly: 8 sachets daily, all of which should be consumed within a 6 hour period.

Children below 12 years old: Not recommended.

Patients with impaired cardiovascular function: For the treatment of faecal impaction the dose should be divided so that no more than 2 sachets are taken in any one hour.

Patients with renal insufficiency: No dosage change is necessary for the treatment of constipation or faecal impaction.


Each sachet should be dissolved in 125 ml water. For use in faecal impaction, 8 sachets may be dissolved in 1 litre of water.

Go to top of the page
4.3 Contraindications

Laxido Orange is contraindicated in intestinal obstruction or perforation caused by functional or structural disorder of the gut wall, ileus and in patients with severe inflammatory conditions of the intestinal tract (e.g. ulcerative colitis, Crohn's disease and toxic megacolon).

Hypersensitivity to the active substances or any of the excipients.

Go to top of the page
4.4 Special warnings and precautions for use

The faecal impaction diagnosis should be confirmed by appropriate physical or radiological examination of the rectum and abdomen.

Mild adverse drug reactions are possible as indicated in Section 4.8. If patients develop any symptoms indicating shifts of fluids/electrolytes (e.g. oedema, shortness of breath, increasing fatigue, dehydration, cardiac failure) Laxido Orange should be stopped immediately and electrolytes measured and any abnormality should be treated appropriately.

The absorption of other medicinal products could transiently be reduced due to an increase in gastro-intestinal transit rate induced by Laxido Orange (see section 4.5)

Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Macrogol 3350 raises the solubility of medicinal products that are soluble in alcohol and mainly insoluble in water. It is a theoretical possibility that absorption of other medicinal products could be reduced transiently during use with Laxido Orange (see Section 4.4). There have been isolated reports of decreased efficacy with some concomitantly administered medicinal products, e.g. anti-epileptics. Therefore, other medicines should not be taken orally for one hour before and for one hour after taking Laxido Orange.

Go to top of the page
4.6 Pregnancy and lactation


There are no or limited amount of data from the use of Laxido Orange in pregnant women. Studies in animals have shown reproductive toxicity (see Section 5.3).


No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to Macrogol 3350 is negligible.

Laxido Orange can be used during breast-feeding.

Go to top of the page
4.7 Effects on ability to drive and use machines

Laxido Orange has no influence on the ability to drive and use machines.

Go to top of the page
4.8 Undesirable effects

Reactions related to the gastrointestinal tract occur most commonly.

These reactions may occur as a consequence of expansion of the contents of the gastrointestinal tract, and an increase in motility due to the pharmacologic effects of Laxido Orange. Mild diarrhoea usually responds to dose reduction.

The frequency of the adverse effects is not known as it cannot be estimated from the available data.

System Order Class

Adverse Event

Immune system disorders

Allergic reactions, including anaphylaxis, angioedema, dyspnoea, rash, erythema, urticaria, and pruritus.

Metabolism and nutrition disorders

Electrolyte disturbances, particularly hyperkalaemia and hypokalaemia.

Nervous system disorders


Gastrointestinal disorders

Abdominal pain, diarrhoea, vomiting, nausea, dyspepsia, abdominal distension, borborygmi, flatulence, anal discomfort.

General disorders and administration site conditions

Peripheral oedema

Go to top of the page
4.9 Overdose

Severe distension or pain can be treated using nasogastric aspiration. Vomiting or diarrhoea may induce extensive fluid loss, possibly leading to electrolyte disturbances that should be treated appropriately.

Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Osmotically acting laxatives.

ATC code: A06A D65

Macrogol 3350 induces a laxative effect through its osmotic action in the gut. This product also contains electrolytes to ensure that there is no overall gain or loss of water, potassium or sodium.

Clinical studies using the listed active substances for the treatment of chronic constipation have shown that the dose required to produce normally formed stools tends to decrease over time. For most patients, the maintenance dose will be one to two sachets per day (adjusted according to individual response).

Comparative studies in faecal impaction using active controls (e.g. enemas) have not been performed. However, results from a non-comparative study have shown that, from a population of 27 adult patients, the listed combination of active substances cleared faecal impaction in 12/27 (44%) patients after one day's treatment, increasing to 23/27 (85%) following two days' treatment and 24/27 (89%) recovered at the end of three days.

Go to top of the page
5.2 Pharmacokinetic properties

Macrogol 3350 is virtually unabsorbed from the gastro-intestinal tract and is excreted, unaltered, in faeces. Any macrogol 3350 that enters the systemic circulation is excreted in urine.

Go to top of the page
5.3 Preclinical safety data

Preclinical studies provide evidence that macrogol 3350 has no significant systemic toxicity potential, based on conventional studies of pharmacology, repeated dose toxicity and genotoxicity.

Indirect embryofoetal effects were noted in the rabbit at clinically relevant doses. Treatment caused an increased incidence of malrotated limbs, reduction in foetal and placental weights, reduced foetal viability and abortions at maternally toxic doses. The safety margin was 1.1 x the maximum recommended dose for faecal impaction in a 60kg adult for malrotated limb and 2.9 x below the maximum recommended dose for the remaining findings. Rabbits are sensitive animal test species to the effects of GI acting substances and the studies were conducted under exaggerated conditions with administered high dose volumes. The relevance of these findings to humans is unknown.

There are no long-term animal toxicity or carcinogenicity studies involving macrogol 3350, although there are toxicity studies using high levels of orally administered high-molecular weight macrogols that provide evidence of safety at the recommended therapeutic dose.

Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Acesulfame Potassium (E950)

Orange Flavour

(Orange flavour contains the following constituents: natural flavouring substances and preparations, maltodextrin and propylene glycol [E1520])

Go to top of the page
6.2 Incompatibilities

Not applicable.

Go to top of the page
6.3 Shelf life

Sachet: Two years.

Reconstituted solution: Six hours.

Go to top of the page
6.4 Special precautions for storage

Sachet: Store below 25°C.

Reconstituted solution: Store covered in a refrigerator (2°C to 8°C).

Go to top of the page
6.5 Nature and contents of container

The sachet is composed of paper, low density polyethylene and aluminium.

Sachets are packed in cartons of 2, 8, 10, 20, 30, 50 and 100.

Not all pack sizes may be marketed.

Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.

Go to top of the page
7. Marketing authorisation holder

Galen Limited

Seagoe Industrial Estate


BT63 5UA


Go to top of the page
8. Marketing authorisation number(s)

PL 27827/0026.

Go to top of the page
9. Date of first authorisation/renewal of the authorisation

01 May 2008.

Go to top of the page
10. Date of revision of the text

31 January 2013.

More information about this product

Link to this document from your website: